Understanding Lower Back Pain and Treatment Options
Prevalence of Lower Back Pain
Lower back pain is a common issue that many individuals face. A systematic analysis for the Global Burden of Disease Study 2017 indicates that it has been the leading cause of disability worldwide for the past three decades.
Role of Muscle Relaxants
Muscle relaxants are frequently prescribed to alleviate low back pain. These medications, which include non-benzodiazepine antispasmodics and antispastics, rank as the third most commonly prescribed drugs for this condition, according to various studies. However, there is conflicting guidance concerning the efficacy and safety of muscle relaxants for treating low back pain.
Recent Findings on Muscle Relaxants
A review published by the BMJ examined all available studies related to low back pain treatment with muscle relaxants. This review incorporated data from 31 studies in a meta-analysis. The findings indicated that certain muscle relaxants, specifically non-benzodiazepine antispasmodics, significantly reduced acute low back pain within the first two weeks of treatment when compared to a control group.
What Are Muscle Relaxants?
Muscle relaxants are typically prescribed alongside rest and physical therapy for muscular injuries. These medications work by depressing the central nervous system, which helps to relax the musculoskeletal system.
Types of Muscle Relaxants
Muscle relaxants can be categorized into different types, including non-benzodiazepine antispasmodics and antispastics.
– **Non-benzodiazepine antispasmodics** target the spinal cord or brain stem and include medications such as cyclobenzaprine, carisoprodol, and metaxalone.
– **Antispastics** are often used for conditions such as cerebral palsy and multiple sclerosis, with examples including baclofen and dantrolene.
Effectiveness of Non-Benzodiazepine Antispasmodics
Research suggests that non-benzodiazepine antispasmodics may offer some benefits for acute back pain. Within the two-week treatment window, these medications demonstrated a significant reduction in pain compared to control groups. However, from weeks three to thirteen, no notable pain reduction was observed when comparing treated individuals to controls. This indicates that while non-benzodiazepine antispasmodics can be beneficial initially, their effectiveness diminishes over time. Additionally, the meta-analysis revealed no reduction in patient disability associated with these medications.
Safety of Muscle Relaxants
The review highlighted that the use of non-benzodiazepine antispasmodics for acute low back pain is linked to an increased risk of adverse effects, although these effects were not classified as serious. The certainty of these findings was rated as low. Furthermore, it was noted that antispastics also raised the risk of adverse events, unlike benzodiazepines, which did not show the same risk level. Patients taking antispastics were more likely to discontinue use due to adverse effects compared to those on non-benzodiazepine antispasmodics.
Implications for Treatment
The authors of the review expressed that while the findings are significant, they may not lead to immediate changes in clinical practice due to the low certainty of the data. They emphasized the necessity for further controlled trials comparing placebo and treatment effects to better assess the benefits and safety of muscle relaxants for low back pain. In the meantime, it is recommended that patients be informed of the potential benefits and safety concerns associated with muscle relaxants before commencing treatment.
References
1. Global Burden of Disease 2017 Disease and Injury Incidence and Prevalence Collaborators. (2019). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet; 393(10190): e44. Doi: 10.1016/S0140-6736(18)32279-7.
2. Gore, M. et al. (2012). Use and Costs of Prescription Medications and Alternative Treatments in Patients with Osteoarthritis and Chronic Low Back Pain in Community-Based Settings. Pain Practice; 12(7): 550-560. Doi: 10.1111/j.1533-2500.2012.00532.x.
3. Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine J. 2011;11(7):622-632. doi:10.1016/j.spinee.2011.03.017.
4. Cashin, A.G. et al. (2021). Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. The BMJ; 374: n1446. Doi: 10.1136/bmj.n1446.
5. Jackson MD, Ryan DM. Drugs of Importance in Rehabilitation. In: JA DeLisa editor(s). Rehabilitation Medicine: Principles and Practice. 2. Philadelphia: J.B. Lippincott Company, 1993.
6. See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008;78(3):365-370. https://www.aafp.org/pubs/afp/issues/2008/0801/p365.html.